Focused On-demand Library for Spatacsin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q96JI7

UPID:

SPTCS_HUMAN

Alternative names:

Colorectal carcinoma-associated protein; Spastic paraplegia 11 protein

Alternative UPACC:

Q96JI7; A8KAX9; B9EK60; F5H3N6; Q4VC11; Q58G86; Q69YG6; Q6NW01; Q8N270; Q8TBU9; Q9H734

Background:

Spatacsin, also known as Colorectal carcinoma-associated protein and Spastic paraplegia 11 protein, plays a crucial role in neurite plasticity. It maintains cytoskeleton stability and regulates synaptic vesicle transport, essential for proper neuronal function.

Therapeutic significance:

Spatacsin's involvement in diseases such as Spastic paraplegia 11, Amyotrophic lateral sclerosis 5, and Charcot-Marie-Tooth disease, highlights its potential as a target for therapeutic strategies. Understanding its role could lead to breakthroughs in treating these neurodegenerative disorders.